Volume | 93,960 |
|
|||||
News | - | ||||||
Day High | 4.33 | Low High |
|||||
Day Low | 3.95 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Eagle Pharmaceuticals Inc | EGRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.05 | 3.95 | 4.33 | 4.05 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
669 | 93,960 | US$ 4.15 | US$ 389,963 | - | 3.95 - 30.40 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
12:44:58 | 12 | US$ 4.255 | USD |
Eagle Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
55.32M | 12.99M | - | 316.61M | 35.64M | 2.74 | 1.55 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eagle Pharmaceuticals News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EGRX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.57 | 5.01 | 3.95 | 4.30 | 116,285 | -0.31 | -6.78% |
1 Month | 4.75 | 5.27 | 3.95 | 4.72 | 163,273 | -0.49 | -10.32% |
3 Months | 5.60 | 6.81 | 3.95 | 5.32 | 171,918 | -1.34 | -23.93% |
6 Months | 13.71 | 14.78 | 3.95 | 5.71 | 222,244 | -9.45 | -68.93% |
1 Year | 28.02 | 30.40 | 3.95 | 11.12 | 190,467 | -23.76 | -84.80% |
3 Years | 40.62 | 58.25 | 3.95 | 27.99 | 152,995 | -36.36 | -89.51% |
5 Years | 52.92 | 64.94 | 3.95 | 36.71 | 151,821 | -48.66 | -91.95% |
Eagle Pharmaceuticals Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration. |